AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLCR. Kumar, S. H. Kim,D. Zhong, S. Lu,Y. Cheng,M. Chen, E. Cho, T. Clay,J. -H. Kang,G. -W. Lee,M. Sun, B. -Y. Shim, D. R. Spigel,T. -Y. Yang, Q. Wang,G. -C. Chang, G. Yu,R. Wang, X. Luo, H. Zheng,R. Gao, H. R. KimJOURNAL OF THORACIC ONCOLOGY（2022）引用 1|浏览8暂无评分关键词TIGIT antibody, PD-1 inhibitor, metastatic NSCLCAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
